Leukotriene Receptor
Leukotriene Receptor (cys-LTs) are a family of potent bioactive lipids that act through two structurally divergent G protein-coupled receptors, termed the CysLT1 and CysLT2 receptors. The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial asthma. Leukotriene Receptor is a member of the superfamily of G protein-coupled receptors and uses a phosphatidylinositol-calcium second messenger system. Activation of CysLT1 by LTD4 results in contraction and proliferation of smooth muscle, oedema, eosinophil migration and damage to the mucus layer in the lung. Leukotriene receptor antagonists, called LTRAs for short, are a class of oral medication that is non-steroidal. They may also be referred to as anti-inflammatory bronchoconstriction preventors. LTRAs work by blocking a chemical reaction that can lead to inflammation in the airways.
Leukotriene Receptor Isoform Specific Products
All Product Categories
-
Leukotriene Receptor Inhibitors
(66)
View all products
-
Leukotriene Receptor Agonists
(10)
View all products
-
Leukotriene Receptor Antagonists
(127)
View all products
-
Leukotriene Receptor Activators
(2)
View all products
-
Leukotriene Receptor Control
(1)
View all products
-
Leukotriene Receptor Substrate
(1)
View all products
-
Leukotriene Receptor Related Products (229)
Related Products (229)
-
Antibodies (1)
-
Leukotriene Receptor Isoform Comparison
-
L-652343
0 ImagesCat. No.: HY-105933CAS No.: 107008-29-7L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (HY-N6687) (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases.
-
5-LOX-IN-6
0 ImagesCat. No.: HY-120502CAS No.: 1159576-98-35-LOX-IN-6 (compound 11a) is a direct and reversible inhibitor of 5-lipoxygenase (5-LO). 5-LOX-IN-6 inhibits 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 and 0.086 µM, respectively. 5-LOX-IN-6 prevents leukotriene biosynthesis. 5-LOX-IN-6 can be used for inflammatory and allergic disorders research.
-
CGP 57698
0 ImagesCat. No.: HY-105712CAS No.: 168082-74-4CGP 57698 is an efficient CysLT receptor (Ki = 5.7 nM) antagonist. CGP 57698 can effectively counteract bronchoconstriction caused by LTD4. CGP 57698 can be used for research on asthma or allergic conditions.
-
5-O-Demethylnobiletin (Standard)
0 Images5-O-Demethylnobiletin (Standard) is the analytical standard of 5-O-Demethylnobiletin. This product is intended for research and analytical applications. 5-O-Demethylnobiletin (5-Demethylnobiletin), a polymethoxyflavone isolated from Citrus jambhiri Lush., is a direct inhibition of 5-LOX (IC50=0.1 μM), without affecting the expression of COX-2. 5-O-Demethylnobiletin (5-Demethylnobiletin) has anti-inflammatory activity, inhibits leukotriene B (4)(LTB4) formation in rat neutrophils and elastase release in human neutrophils with an IC50 of 0.35 μM.
-
Tipelukast-d6
0 ImagesCat. No.: HY-W744275Tipelukast-d6 is the deuterium labeled Tipelukast (HY-14938). Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.
-
Bisisorhapontigenin A
0 ImagesCat. No.: HY-N16543CAS No.: 332381-09-6Bisisorhapontigenin A is a dimer of isorhapontigenin. Bisisorhapontigenin A exhibits antagonistic activity against LTD4 and can be used for research on anti-inflammatory effects.
-
Leukotriene B5
0 ImagesCat. No.: HY-113484CAS No.: 80445-66-5Synonyms: LTB5Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
-
12(S)-HEPE
0 ImagesCat. No.: HY-W747548CAS No.: 116180-17-712(S)-HEPE is a monohydroxy fatty acid synthesized from EPA by the action of 12-LO. Unstimulated neutrophils metabolize 12(S)-HEPE to 12(S),20-diHEPE, whereas stimulated neutrophils produce 5(S),12(S)-HEPE via the 5-lipoxygenase pathway. The competitive action of 12(S)-HEPE with arachidonic acid as a substrate for 5-LO in the formation of leukotrienes may provide a basis for the anti-inflammatory potential of ω-3 fatty acids.
-
JNJ-40929837
0 ImagesCat. No.: HY-156960CAS No.: 1191044-42-4JNJ-40929837 is a selective and orally active LTA4H (leukotriene A4 hydrolase) inhibitor. JNJ-40929837 effectively inhibits aminopeptidase activity and causes serum accumulation of Pro-Gly-Pro. JNJ-40929837 can be used in asthma research.
-
SC-41930
0 ImagesCat. No.: HY-112739CAS No.: 120072-59-5SC-41930 is a orally active eukotriene-B4 receptor antagonist. SC-41930 alleviates inflammation in guinea pig acetic acid-induced colonic inflammation model.
-
Montelukast dicyclohexylamine (Standard)
0 ImagesCat. No.: HY-13315BRCAS No.: 577953-88-9Synonyms: MK0476 dicyclohexylamine (Standard)Montelukast (dicyclohexylamine) (Standard) is the analytical standard of Montelukast (dicyclohexylamine). This product is intended for research and analytical applications. Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1). Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research.
-
(S)-Verapamil-d7 (hydrochloride)
0 ImagesCat. No.: HY-135336ASCAS No.: 2967473-85-2Synonyms: (S)-(-)-Verapamil-d7 (hydrochloride)(S)-Verapamil-d7 (hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells.
-
BLT2 antagonist-1
0 ImagesCat. No.: HY-155300CAS No.: 2069220-61-5BLT2 antagonist-1 (compound 15b) is a selective BLT2 antagonist that inhibits the chemotaxis of CHO-BLT2 cells with an IC50 of 224 nM. BLT2 antagonist-1 does not inhibits the chemotaxis of CHO-BLT1 cells. BLT2 antagonist-1 also inhibits the binding of LTB4 and BLT2 with a Ki value of 132 nM. BLT2 antagonist-1 can be used for the research of the inflammatory airway diseases such as asthma and chronic obstructive pulmonary disease.
-
Sch 33303
0 ImagesCat. No.: HY-119055CAS No.: 89108-58-7Sch 33303 is an orally active antiallergy agent that inhibits the release of the sulfidopeptide leukotrienes. Sch 33303 is promising for research of asthma.
-
Camellia nitidissima flavone glycoside B
0 ImagesCat. No.: HY-N21989CAS No.: 1620808-64-1Synonyms: Kaempferol 3-O-β-D-glucopyranosyl-(1→3)[α-L-rhamnopyranosyl(1→6)]-(2-O-E-p-coumaroyl-β-D-glucopyranoside)Camellia nitidissima flavone glycoside B (Kaempferol 3-O-β-D-glucopyranosyl-(1→3)[α-L-rhamnopyranosyl(1→6)]-(2-O-E-p-coumaroyl-β-D-glucopyranoside)) is an anti-allergic asthma compound. Camellia nitidissima flavone glycoside B can be isolated from the leaves of Camellia nitidissima. Camellia nitidissima flavone glycoside B inhibits leukotriene production. Camellia nitidissima flavone glycoside B can be used in the research of allergic asthma.
-
T-10430
0 ImagesCat. No.: HY-168484CAS No.: 3083523-06-9T-10430 is a potent and orally active leukotriene B4 receptor 2 (BLT2) agonist. T-10430 has the potential for the research of psoriasis.
-
Leukotriene B4-3-aminopropylamide
0 ImagesCat. No.: HY-W747565CAS No.: 89596-43-0Synonyms: LTB4-APALeukotriene B4-3-aminopropylamide (LTB4-APA) is a leukotriene immunomodulator.
-
YM-16638
0 ImagesCat. No.: HY-19042CAS No.: 104073-72-5Synonyms: YM 638YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC4, LTD4, and LTE4 in guinea pig trachea, with IC50 values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep.
-
2-ARA-LysoPtdEtn
0 ImagesCat. No.: HY-185709CAS No.: 53847-31-7Synonyms: 1-Lyso-2-arachidonoyl-sn-glycero-3-phosphoethanolamine2-ARA-LysoPtdEtn (1-Lyso-2-arachidonoyl-sn-glycero-3-phosphoethanolamine) is an orally active polyunsaturated acyl lysophosphatidylethanolamine. 2-ARA-LysoPtdEtn diminishes formation of LTC4, LTB4, and 12-HETE. 2-ARA-LysoPtdEtn lowers levels of IL-1β, IL-6, TNF-α, and NO. 2-ARA-LysoPtdEtn augments IL-10 levels and upgrades formation of 15-HETE and LXA4. 2-ARA-LysoPtdEtn can be used for the research of peritonitis.
-
SR2640
0 ImagesCat. No.: HY-136831CAS No.: 105350-26-3Synonyms: QMPBSR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research.
